LimPrOn: Limburg Pre-eclampsia Investigation

Status: Recruiting
Location: See all (8) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Background: Multiple adaptations at the cardiovascular system occurs during pregnancy. In the pregnancy condition pre-eclampsia (PE), this adaptations are abnormal. Five to eight percent of all pregnant women worldwide will develop PE. PE is a pregnancy condition which is characterized with a high blood pressure (\>140/90 mm Hg) and the occurrence of proteinuria (\>3g/dl/24h) after 20 weeks of gestation. When untreated, this condition can have severe complications for both mother and child. It's important to monitor women with a high risk for developing PE for an early detection and treatment of this condition. For this reason, a multicenter study is set up with the following applications: 1. NICCOMO and Maternal Venous Doppler Echography: impedance cardiograph and an echography of the heart and veins. 2. Maltron: bio-electronic impedance analyze 3. Remote monitoring of the high risk patients to become a more intensive follow-up Number of inclusions: 2000 pregnant women from the prenatal consultations of eight different hospitals:

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: t
View:

• \> 10 weeks of pregnancy, primipara and multipara

Locations
Other Locations
Belgium
Ziekenhuis Maas en Kempen
RECRUITING
Bree
Ziekenhuis Oost-Limburg
RECRUITING
Genk
Jessa Ziekenhuis
RECRUITING
Hasselt
Sint-Fransiscus Ziekenhuis
RECRUITING
Heusden-zolder
Heilig Hart Ziekenhuis
RECRUITING
Mol
Mariaziekenhuis Oost-Limburg
RECRUITING
Overpelt
Sint-Trudo ziekenhuis
RECRUITING
Sint-truiden
AZ-vesalius
RECRUITING
Tongeren
Contact Information
Primary
Dorien Lanssens, drs.
dorien.lanssens@uhasselt.be
Time Frame
Start Date: 2016-05
Estimated Completion Date: 2030-12
Participants
Target number of participants: 2000
Treatments
No_intervention: Control Group
Experimental: remote monitoring group
Related Therapeutic Areas
Sponsors
Leads: Hasselt University
Collaborators: Ziekenhuis Oost-Limburg

This content was sourced from clinicaltrials.gov